-
CASH 2026 | Professor Zhijian Xiao: Precision Risk Stratification and Emerging Therapeutic Advances in MDS
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health priorities. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Zhijian Xiao from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of…
-
CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of…
-
CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic…
-
CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation
As an emerging modality of hematopoietic stem cell transplantation, umbilical cord blood transplantation (UCBT) has demonstrated unique clinical value in the treatment of various hematologic diseases. From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading hematology experts from China and abroad to explore cutting-edge research…
-
Annual Review | Professor Wei Xu: New Trends and Future Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the meeting, Professor Wei Xu from Jiangsu Provincial People’s Hospital provided a comprehensive review of key advances in CLL treatment, therapeutic decision-making in high-risk disease, and future research directions,…
-
Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer
HER2-positive breast cancer was once associated with aggressive behavior and poor prognosis. However, with the rapid advancement of targeted therapies—particularly antibody–drug conjugates (ADCs)—this subtype has evolved into a highly treatable and potentially curable disease. In 2025, landmark studies across neoadjuvant, adjuvant, and metastatic settings have reshaped treatment paradigms toward greater precision and individualization. During the…
-
2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes
The 2025 Yixian Breast Cancer Conference, held alongside the 2025 CSCO Breast Cancer Southern Forum, the Second Chinese Young Breast Cancer Consensus Conference, and the Fourth Yixian Breast Cancer Nursing Conference, took place in Guangzhou on December 26–27, 2025. The meeting focused on standardization of breast cancer care, emerging therapeutic strategies, and precision management in…
-
Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines
As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under…
Connecting Medical Expertise through Media